Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis

Fig. 4

Summary of the primary safety outcome. A Network plot of serious adverse events. The width of the lines is proportional to the number of studies comparing every pair of treatments, and the size of each circle is proportional to the number of participants. B The forest plot shows the risk ratio (RR) and credible interval (CrI). C SUCRA-based ranking probabilities graph of each medication. The SUCRA values for each treatment were as follows: 77% for alirocumab; 20% for evolocumab; 83% for inclisiran. SUCRA surface under the cumulative ranking curve

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840